RxDoctor Payments Data

Joseph Cappa, MD

Gastroenterology · Glastonbury, CTNPI 1639273212

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $135,690 of the $200,204 with a category attached, or 67.8%. 39 manufacturers reported payments, led by Johnson & Johnson at 33.3% of the total. Among gastroenterology clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$200,204in general payments, 2019–2025

Across 647 payments — averaging $309.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$67K
  • E.r. Squibb & Sons, L.L.C.$42K
  • Janssen Scientific Affairs, LLC$35K
  • Pfizer$20K
  • Takeda Pharmaceuticals U.S.A., Inc.$10K
  • AbbVie$6K
  • plus $19K from 33 others

What the payments were for

  • Consulting fees$28,63714%
  • Speaking & faculty fees$135,69068%
  • Travel & lodging$16,2108%
  • Food & beverage$19,02010%
  • Education$1680%
  • Other$4790%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$200,204 in reported general payments places this provider in the 95th percentile of 326 gastroenterology providers in Connecticut.

See all gastroenterology providers in Connecticut

Medicare billing

Part B allowed, 2024
$161,819
Medicare patients
194
Services billed
6,924

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab14$419,867
SutabSod Sulf/Pot Chloride/Mag Sulf65$10,642
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates67$4,083
SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag12$1,413
Pantoprazole Sodium91$793
Omeprazole36$724
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg21$478

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$66,661$419,86714 claims
Braintree Laboratories, Inc.Sutab, Suflave$42$12,05577 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 326 gastroenterology providers in Connecticut.

Other gastroenterology in Glastonbury

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →